Mga Batayang Estadistika
| CIK | 1757064 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Genfit S.A. - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| July 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 8, 2025 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal execu |
|
| July 8, 2025 |
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial Exhibit 99.1 GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidit |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 17, 2025 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal exec |
|
| June 17, 2025 |
Exhibit 99.1 GENFIT: June 17, 2025 Combined Shareholders Meeting Results - All resolutions recommended by the Board of Directors approved (quorum: 27.21%). Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver di |
|
| May 22, 2025 |
GENFIT Reports First Quarter 2025 Financial Information Exhibit 99.1 GENFIT Reports First Quarter 2025 Financial Information Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of March 31, 2025 and revenues f |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 22, 2025 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal execu |
|
| May 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 20, 2025 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal execu |
|
| May 20, 2025 |
Exhibit 99.1 GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen’s Iqirvo® in Italy Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 20, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, toda |
|
| May 14, 2025 |
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024) Exhibit 99.1 GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024) Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the publication of its 2025 Extra-F |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 14, 2025 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal execu |
|
| May 7, 2025 |
Exhibit 99.2 MAY 7, 2025 FRENCH OFFICIAL LEGAL ANNOUNCEMENTS PUBLICATION «BALO» BULLETIN N°55 This document has been translated in English for information only. In the event of any differences between the French text and the English text, the French language version shall supersede. GENFIT French public limited company (Société Anonyme) with a Board of Directors With share capital of 12.499.046,25 |
|
| May 7, 2025 |
GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents Exhibit 99.1 GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); May 7, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it published in the |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 7, 2025 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal execut |
|
| May 5, 2025 |
GENFIT to Present Latest ACLF Research at EASL Congress 2025 Exhibit 99.1 GENFIT to Present Latest ACLF Research at EASL Congress 2025 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 5, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces its participation at the European Association for the Study |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 5, 2025 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal execut |
|
| April 29, 2025 |
DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Exhibit 2.3 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the ordinary shares, the American Depositary Shares and the articles of association, or bylaws, of GENFIT S.A. (“Genfit” or the “Company”) is a summary and does not purport to be complete. This summary is subject to, and qualified in its entirety by reference |
|
| April 29, 2025 |
Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of GENFIT S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Thomas Baetz, Chi |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 29, 2025 |
Exhibit 4.18 Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. Execution Version Royalty Bond Support Agreement Between Genfit S.A. AND HCRX Investments HoldCo, L.P. Dated as of January 30, 2025 Table of Contents Page ARTICLE I Definitions; Interpretation 2 Sec |
|
| April 29, 2025 |
Summary of the 2025 Stock Options Plans Exhibit 4.12 Summary of the 2025 Stock Options Plans Stock options (options de souscription et/ou d’achat d’actions) are granted for free and entitle each holder to subscribe for new shares and/or purchase existing shares of our Company at an exercise price set at the time of grant. Administration. Pursuant to delegations granted at our general meeting of the shareholders, our board of directors d |
|
| April 29, 2025 |
CLIFFORD CHANCE LLP Certain information has been excluded from this agreement (indicated by “[***]” because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed SUBSCRIPTION AGREEMENT relating to a 9,250,000 issuance of Euro denominated bonds (obligations) dated 30 January 2025 between GENFIT SA as Issuer and HCRX INVESTMENTS HOLDCO, L. |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 29, 2025 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal exe |
|
| April 29, 2025 |
BETWEEN GENFIT SA AS ISSUER HCRX INVESTMENTS HOLDCO, L.P. AS SUBSCRIBER Certain information has been excluded from this agreement (indicated by “[***]” because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed dated 12 March 2025 BETWEEN GENFIT SA AS ISSUER AND HCRX INVESTMENTS HOLDCO, L. |
|
| April 29, 2025 |
Summary of 2025 Free Shares (AGA) Plans Exhibit 4.4 Summary of 2025 Free Shares (AGA) Plans Free shares or AGA (actions gratuites) are shares of our Company that are granted to the beneficiary for free. They vest (i.e. the grant becomes definitive) after a minimum vesting period of one (1) year and can be subject to a lock-up period of at least one (1) further year. The sum of the vesting period and the lock-up period cannot be less tha |
|
| April 29, 2025 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Thomas Baetz, certify that: 1.I have reviewed this annual report on Form 20-F of GENFIT S.A. (the “Company”); 2.Based on my knowledge, this report does not contain any untrue statement of a material f |
|
| April 29, 2025 |
Exhibit 1.1 GENFIT SA Corporation with a Board of Directors and a share capital of € 12,499,046.25 Registered office: Parc Eurasanté, 885 Avenue Eugène Avinée, 59120 LOOS 424 341 907 R.C.S. LILLE Métropole ARTICLES OF ASSOCIATION Updated as of December 12, 2024 1 Exhibit 1.1 PART I FORM - NAME - REGISTERED OFFICE - PURPOSE - TERM ARTICLE 1 - Form The owners of the shares created below and of those |
|
| April 29, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form F-3 No. 333-271312) of Genfit S.A., and (2) Registration Statement (Form S-8 No. 333-271311) pertaining to the 2019 BSA Plan, 2021, 2022 and 2023 Free Share (AGA) Plans, and 2016, 2017, 2018, 2019, 2020, 2021, |
|
| April 29, 2025 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Pascal Prigent, certify that: 1.I have reviewed this annual report on Form 20-F of GENFIT S.A. (the “Company”); 2.Based on my knowledge, this report does not contain any untrue statement of a material |
|
| April 29, 2025 |
Exhibit 99.1 GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 29, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces the f |
|
| April 29, 2025 |
Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of GENFIT S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Pascal Prigent, C |
|
| April 29, 2025 |
Exhibit 11.1 INSIDER TRADING POLICY Relating to the confidentiality of Inside Information and the prevention of Insider trading and dealing within the Group Updated on 13 April 2023 TABLE OF CONTENT 1 OBJECTIVES OF THE POLICY 2 DEFINITIONS OF RECURRING TERMS 3 DEFINITION OF INSIDE INFORMATION 4 DEFINITION OF THE CONCEPT OF INSIDER 5 OBLIGATIONS OF THE GROUP 6 OBLIGATIONS OF INSIDERS 7 OFFENCES AND |
|
| April 29, 2025 |
Exhibit 4.17 GENFIT French société anonyme with a board of directors with a share capital of € 7,791,609.25 Registered office: Parc Eurasanté, 885, avenue Eugène Avinée, 59120 Loos, France 424 341 907 R.C.S. Lille Métropole GENFIT 3.50 per cent. bonds issue for a nominal amount of € 179,999,997.60 due 16 October 2025 convertible into new Shares and/or exchangeable for existing Shares of GENFIT AME |
|
| April 28, 2025 |
GENFIT: positive late-breaking Phase 2 data for elafibranor in Exhibit 99.1 GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liv |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 28, 2025 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal exe |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 24, 2025 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal exe |
|
| April 24, 2025 |
GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update Exhibit 99.1 GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update ▪ Cash and cash equivalents totaled €81.8 million as of December 31, 2024. In addition, completion in early 2025 of: (i) a non-dilutive royalty financing agreement for up to €185 million including a first installment of €130 million and (ii) the debt repurchase offer ▪ Net profit of €1.5 million thanks to re |
|
| March 20, 2025 |
Exhibit 99.1 GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders · GENFIT completes a royalty financing of up to €185 million with HCRx after unanimous OCEANE bondholder approval, triggering a €130 million upfront payment with potential for an additional €55 million upon achieving near-term milestones · Non-dilut |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 20, 2025 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal exe |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 10, 2025 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal exe |
|
| March 10, 2025 |
Exhibit 99.1 Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs • All resolutions approved by bondholders • Closing of Royalty Financing and receipt of first €130 million instalment expected shortly • Upon closing of the Royalty Financing, GENFIT will implement the Repurchase of the 2025 OCEANEs and pay the Consent Fee Lille (Fra |
|
| February 27, 2025 |
GENFIT Announces Revenues and Cash Position as of December 31, 2024 Exhibit 99.1 GENFIT Announces Revenues and Cash Position as of December 31, 2024 · Cash and cash equivalents totaled €81.8 million as of December 31, 2024 · Revenues amounted to €67.0 million as of December 31, 2024 including the €48.7 million milestone upon first sale of Ipsen’s Iqirvo® (elafibranor) in the U.S. for the treatment of Primary Biliary Cholangitis (PBC) Lille (France), Cambridge (Mas |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: February 27, 2025 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal |
|
| February 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: February 21, 2025 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal |
|
| February 21, 2025 |
Exhibit 99.1 GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders’ general meeting · Put Option Agreements signed to date with 2025 OCEANEs holders representing 95.3% of the outstanding 2025 OCEANEs · 2025 OCEANEs holders' general meeting convened for March 10, 2025 Lille (France), Cambridge (Massachusetts, United St |
|
| February 14, 2025 |
GENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2025 OCEANEs Holders Exhibit 99.1 GENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2025 OCEANEs Holders · In conjunction with (i) the royalty financing deal with HealthCare Royalty (HCRx) announced on January 30, 2025, and (ii) the final terms of the dual proposal to the 2025 OCEANEs holders announced on February 10, 2025, GENFIT will seek the consent of the holders of 2025 OCEANEs and pro |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: February 14, 2025 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal |
|
| February 10, 2025 |
GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders Exhibit 99.1 GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders • In conjunction with the royalty financing deal with HealthCare Royalty (HCRx) announced on January 30, 2025, GENFIT will request the consent of the holders of 2025 OCEANEs and proposes: • to repurchase the 2025 OCEANEs at EUR 32.00 per bond from interested bondholders, or alternatively • to pay a consent fee |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: February 10, 2025 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal |
|
| February 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: February 6, 2025 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal e |
|
| February 6, 2025 |
Exhibit 99.1 GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025 · 2 new ACLF clinical trials expected to initiate in 1Q25 · 3 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including on- going UNVEIL-IT® Phase 2 trial · Data of on-going Phase 1b also expected by year-end 2025 for GNS561/trametinib in KRAS- mutate |
|
| January 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: 30/01/2025 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal executi |
|
| January 30, 2025 |
GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan Exhibit 99.1 GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan · GENFIT signs royalty financing deal with HealthCare Royalty (HCRx) providing up to €185 million non-dilutive capital: o €130 million upfront, with eligibility to receive up to €55 million in two additional instalments based on near-term milestones o Closing subject to approval by the 2025 OCE |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: 29/01/2025 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal executi |
|
| January 29, 2025 |
GENFIT Announces 2025 Financial Calendar Exhibit 99.1 GENFIT Announces 2025 Financial Calendar Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 29, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2025. 2025 Financial Cale |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: 13 January 2025 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal ex |
|
| January 13, 2025 |
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial Exhibit 99.1 GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 13, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report o |
|
| November 13, 2024 |
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024 Exhibit 99.1 GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024 · PBC program (licensed to Ipsen): o Ipsen to present new data on elafibranor at The Liver Meeting® 2024 o Launch of Iqirvo® (elafibranor)1 on track with expectations; encouraging feedback from healthcare providers and payers in the U.S. o UK NICE reimbursement approved and first reimbursed sales |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: 13 November 2024 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal e |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 7, 2024 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal e |
|
| November 7, 2024 |
GENFIT Reports Third Quarter 2024 Financial Information Exhibit 99.1 GENFIT Reports Third Quarter 2024 Financial Information · Cash and cash equivalents totaled €96.0 million as of September 30, 2024 · €59.7 million in revenues for the nine months ended September 30, 2024, including the €48.7 million milestone invoiced in June 2024 (received in August 2024) upon first sale of Ipsen’s Iqirvo® (elafibranor) in the U.S. for the treatment of Primary Biliar |
|
| September 23, 2024 |
Exhibit 99.1 GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in- Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 23, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 23, 2024 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal |
|
| September 19, 2024 |
GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update Exhibit 99.1 GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update • Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone invoiced in June 2024 (received in August 2024) upon first sale of Ipsen’s Iqirvo® (elafibranor) in the U.S. for the treatment of Primary Biliary Cholangitis (PBC) • €59.0 million in revenues, i |
|
| September 19, 2024 |
Half-Year Business and Financial Report at June 30, 2024 Table of Contents 1. OVERVIEW OF THE GROUP AND ITS MAIN R&D PROGRAMS 2 2. HALF-YEAR MANAGEMENT REPORT 4 2.1 Key Events of the First Half of 2024 and Main Events after the Reporting Period 4 2.2 Strategy and Outlook 6 2.3 Operating and Financial Review 8 2.4 Main Transactions with Related Parties 12 2.5 Main Risks and Uncertainties 12 3. HALF |
|
| September 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 19, 2024 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal |
|
| September 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: 19 September 2024 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal |
|
| July 26, 2024 |
Exhibit 99.1 GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced |
|
| July 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 26, 2024 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal exec |
|
| July 9, 2024 |
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial Exhibit 99.1 GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) July 9, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of th |
|
| July 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 9, 2024 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal execu |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 17, 2024 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal exec |
|
| June 17, 2024 |
Exhibit 99.1 GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, toda |
|
| June 11, 2024 |
Exhibit 99.1 GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis § Ipsen’s Iqirvo® (elafibranor) 80 mg tablets receives U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Cholangitis (PBC) § First-ever drug developed in-house by GENFIT to achieve U.S. FDA’s approval § GENFIT is eligible to receive a |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 10, 2024 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal exec |
|
| May 29, 2024 |
GENFIT to Present Latest ACLF Research at EASL Congress™ 2024 Exhibit 99.1 GENFIT to Present Latest ACLF Research at EASL Congress™ 2024 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today detailed its presence at the EASL Congress™ 2024. GENFIT |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 29, 2024 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal execu |
|
| May 22, 2024 |
Exhibit 99.1 GENFIT: May 22, 2024 Combined Shareholders Meeting Results - Quorum of 27.25% on first convening; allowing approval of all the resolutions Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening li |
|
| May 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 22, 2024 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal execu |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 14, 2024 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal execu |
|
| May 14, 2024 |
GENFIT Reports First Quarter 2024 Financial Information Exhibit 99.1 GENFIT Reports First Quarter 2024 Financial Information Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of March 31, 2024 and revenues f |
|
| April 25, 2024 |
GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023) Exhibit 99.1 GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023) Lille (France), Cambridge (Massachusetts, USA), Zurich (Switzerland), April 25, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases, today announced the publication of its 2024 Extra- |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 25, 2024 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal exe |
|
| April 15, 2024 |
Exhibit 99.2 APRIL 15, 2024 FRENCH OFFICIAL LEGAL ANNOUNCEMENTS PUBLICATION «BALO» BULLETIN N°46 This document has been translated in English for information only. In the event of any differences between the French text and the English text, the French language version shall supersede. SHAREHOLDERS' MEETING GENFIT French public limited company (Société Anonyme) with a Board of Directors With share |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 15, 2024 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal exe |
|
| April 15, 2024 |
GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents Exhibit 99.1 GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it publ |
|
| April 5, 2024 |
Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of GENFIT S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Thomas Baetz, Chi |
|
| April 5, 2024 |
Exhibit 1.1 GENFIT SA Corporation with a Board of Directors and a share capital of € 12,458,745.75 Registered office: Parc Eurasanté, 885 Avenue Eugène Avinée, 59120 LOOS 424 341 907 R.C.S. LILLE Métropole ARTICLES OF ASSOCIATION Updated as of May 24, 2023 1 Exhibit 1.1 PART I FORM - NAME - REGISTERED OFFICE - PURPOSE - TERM ARTICLE 1 - Form The owners of the shares created below and of those that |
|
| April 5, 2024 |
DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Exhibit 2.3 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the ordinary shares, the American Depositary Shares and the articles of association, or bylaws, of GENFIT S.A. (“Genfit” or the “Company”) is a summary and does not purport to be complete. This summary is subject to, and qualified in its entirety by reference |
|
| April 5, 2024 |
Summary of the 2024 Stock Options Plans Exhibit 4.13 Summary of the 2024 Stock Options Plans Stock options (options de souscription et/ou d’achat d’actions) are granted for free and entitle each holder to subscribe for new shares and/or purchase existing shares of our Company at an exercise price set at the time of grant. Administration. Pursuant to delegations granted at our general meeting of the shareholders, our board of directors d |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 05, 2024 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal exe |
|
| April 5, 2024 |
Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of GENFIT S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Pascal Prigent, C |
|
| April 5, 2024 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Pascal Prigent, certify that: 1.I have reviewed this annual report on Form 20-F of GENFIT S.A. (the “Company”); 2.Based on my knowledge, this report does not contain any untrue statement of a material |
|
| April 5, 2024 |
Summary of 2024 Free Shares (AGA) Plans Exhibit 4.6 Summary of 2024 Free Shares (AGA) Plans Free shares or AGA (actions gratuites) are shares of our Company that are granted to the beneficiary for free. They vest (i.e. the grant becomes definitive) after a minimum vesting period of one (1) year and can be subject to a lock-up period of at least one (1) further year. The sum of the vesting period and the lock-up period cannot be less tha |
|
| April 5, 2024 |
Exhibit 99.1 GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 5, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today annou |
|
| April 5, 2024 |
GENFIT Compensation Recovery Policy Adopted by the Board of Directors on March 28, 2023 Exhibit 97.1 GENFIT Compensation Recovery Policy Adopted by the Board of Directors on March 28, 2023 Policy Statement The Board of Directors has established this Compensation Recovery Policy (the “Policy”) in order to comply with the Nasdaq listing standards relating to recovery of erroneously awarded executive compensation (the “Nasdaq Listing Rules”) that will be adopted by Nasdaq as required by |
|
| April 5, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form F-3 No. 333-271312) of Genfit S.A., and (2) Registration Statement (Form S-8 No. 333-271311) pertaining to the 2019 BSA Plan, 2021, 2022 and 2023 Free Share (AGA) Plans, and 2016, 2017, 2018, 2019, 2020, 2021, |
|
| April 5, 2024 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Thomas Baetz, certify that: 1.I have reviewed this annual report on Form 20-F of GENFIT S.A. (the “Company”); 2.Based on my knowledge, this report does not contain any untrue statement of a material f |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 04, 2024 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal exe |
|
| April 4, 2024 |
Exhibit 99.1 GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update – Cash and cash equivalents totaled €77.8 million as of December 31, 2023 – Revenues amounted to €28.6 million as of December 31, 2023 including a milestone payment of €13.3 million – Topline interim data for Phase 2 UNVEIL-IT® trial in ACLF expected in 2H24 – FDA PDUFA action date for elafibranor in PBC: Ju |
|
| February 29, 2024 |
GENFIT Announces Revenues and Cash Position as of December 31, 2023 Exhibit 99.1 GENFIT Announces Revenues and Cash Position as of December 31, 2023 · Cash and cash equivalents totaled €77.8 million as of December 31, 2023 · Revenues amounted to €28.6 million as of December 31, 2023 including a milestone payment of €13.3 million · Upcoming FDA PDUFA action date for elafibranor in PBC: June 10, 2024 Lille (France), Cambridge (Massachusetts, United States), Zurich ( |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: 29 February 2024 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal e |
|
| February 14, 2024 |
GNFTF / Genfit S.A. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 o117246sc13ga1.htm AMENDMENT NO. 1 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Genfit S.A. (Name of Issuer) Ordinary Shares, nominal value €0.25 per share (Title of Class of Securities) 372279109** (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appr |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 15, 2024 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal e |
|
| January 17, 2024 |
GENFIT Announces 2024 Financial Calendar Exhibit 99.1 GENFIT Announces 2024 Financial Calendar Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2024. 2024 Financial Cale |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: 11/01/2024 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal executi |
|
| January 11, 2024 |
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial Exhibit 99.1 GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 11, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report o |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: December 08, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal |
|
| December 8, 2023 |
Exhibit 99.1 GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC) ■ US Food and Drug Administration (FDA) has granted Priority Review for New Drug Application (NDA) for elafibranor in PBC, and European Medicine Agency (EMA) has also validated the Marketing Authorization Application (MAA) for elafibranor. ■ Acceptance triggers a first mileston |
|
| December 7, 2023 |
Exhibit 99.1 Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC · New Drug Application granted priority review with PDUFA date set for June 10, 2024 · European Medicines Agency (EMA) has also validated the Marketing Authorization Application (MAA) for elafibranor · Investigational elafibranor is the first |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: December 7, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal e |
|
| December 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: December 6, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal e |
|
| December 6, 2023 |
Exhibit 99.1 GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials · The paper published in Journal of Hepatology demonstrates that NIS2+™ technology could significantly reduce liver biopsy failure rate and maximizes accuracy of patient selection for MASH1 clinical trials · Growing |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 16, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal |
|
| November 16, 2023 |
GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023 Exhibit 99.1 GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023 § GENFIT highlighted new focus and development strategy in Acute On-Chronic Liver Failure (ACLF) § ACLF is a very serious condition affecting ~294,0001 2 patients with chronic liver diseases in the USA and Europe every year and is associated with multi-organ failure and high short-term morta |
|
| November 13, 2023 |
Exhibit 99.1 GENFIT: Results from Ipsen's ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine · ELATIVE® Phase III trial confirms potential for investigational elafibranor as a novel, first-in-class, dual PPAR α,δ agonist for patients with Primary Biliary Cholangitis. · Elafibranor demonstrates si |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 13, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal |
|
| November 9, 2023 |
GENFIT Reports Third Quarter 2023 Financial Information Exhibit 99.1 GENFIT Reports Third Quarter 2023 Financial Information · Cash and cash equivalents totaled €93.9 million as of September 30, 2023 Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); November 9, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 09, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 02, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal |
|
| November 6, 2023 |
GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023 Exhibit 99.1 GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023 · GENFIT to lead 3 key events on ACLF during AASLD: o ACLF Day for Investors/Analysts on November 11, 2023 o Patient Advocacy Council meeting on November 11, 2023 o ACLF Investigator event on November 12, 2023 · Detailed interim data from the ELATIVE® Phase 3 results evaluating elafibranor in PBC |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 26, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal |
|
| September 26, 2023 |
Exhibit 99.1 GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); September 26, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the |
|
| September 20, 2023 |
Half-Year Business and Financial Report at June 30, 2023 Half-Year Business and Financial Report at June 30, 2023 Table of Contents 1. |
|
| September 20, 2023 |
GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update Exhibit 99.1 GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update • Cash, cash equivalents and current financial assets totaled €111.8 million as of June 30, 2023 • Positive results in the pivotal Phase 3 ELATIVE® trial in June 2023, paving the way to: – a potential submission to the health authorities by Ipsen, and a potential first milestone met before the end of 2 |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 20, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 20, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 5, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal |
|
| September 5, 2023 |
GENFIT to Participate in Upcoming Investor Conferences Exhibit 99.1 GENFIT to Participate in Upcoming Investor Conferences Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 05, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it will participate in the following upcoming investo |
|
| August 10, 2023 |
Exhibit 99.1 GENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+™ in Older Patients in Hepatology Communications Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); August 10, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, to |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: August 10, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal ex |
|
| July 12, 2023 |
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial Exhibit 99.1 GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) July 12, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the half-year report of the liquidi |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 12, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal exec |
|
| June 30, 2023 |
Exhibit 99.1 Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease - Trial met primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to placebo - Elafibranor was well tolerated with a safety profil |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 30, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal exec |
|
| June 7, 2023 |
Exhibit 99.1 GENFIT Announces New Data at the European Association for the Study of the Liver (EASL) Congress 2023 Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); June 7, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it will pres |
|
| June 7, 2023 |
6-K 1 f6k060723.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 07, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, Fran |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 31, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal execu |
|
| May 31, 2023 |
GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset Exhibit 99.1 GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset § Exclusive worldwide rights licensed from Seal Rock Therapeutics for injectable formulation of ASK1 Inhibitor SRT-015 in acute liver disease § Preclinical and clinical evidence support ASK1 inhibition as a relevant therapeutic strategy in multi-system disorders such as Acute-on-Chronic Liver Failure (ACLF |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 24, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal execu |
|
| May 24, 2023 |
GENFIT: May 24, 2023 Combined Shareholders Meeting results Exhibit 99.1 GENFIT: May 24, 2023 Combined Shareholders Meeting results · Quorum of 29.54% on first convening; allowing approval of all the resolutions recommended by the Board of Directors Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); May 24, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of pati |
|
| May 23, 2023 |
Exhibit 99.1 GENFIT Announces Publication of the Development and Validation of NIS2+™ in the Journal of Hepatology Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); May 23, 2023- GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the publication of |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 23, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal execu |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant's name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal executiv |
|
| May 11, 2023 |
Exhibit 99.1 GENFIT Reports First Quarter 2023 Financial Information1 – Cash, cash equivalents and current financial assets totaled €128.6 million as of March 31, 2023 Lille (France); Cambridge, (Massachusetts, United States); Zurich (Switzerland); May 11, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and se |
|
| May 9, 2023 |
Exhibit 99.1 GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week® as part of its ACLF Program Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); May 9, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it is p |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 9, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant's name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal execut |
|
| May 2, 2023 |
May 2, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford Re: GENFIT S.A. Registration Statement on Form F-3 Filed April 18, 2023 File No. 333-271312 Acceleration Request Requested Date: May 4, 2023 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Se |
|
| May 1, 2023 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Ordinary Shares, €0.25 nominal value per share, of Genfit S.A. and further agree to the filing of this a |
|
| May 1, 2023 |
GNFTF / Genfit / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 28, 2023 |
GENFIT Announces Publication of Extra-Financial Performance Report 2022 Exhibit 99.1 GENFIT Announces Publication of Extra-Financial Performance Report 2022 Lille (France); Cambridge, (Massachusetts, United States); Zurich (Switzerland); April 27, 2023- GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the publication of its Extra-Financial Perfor |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 27, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal exe |
|
| April 19, 2023 |
GENFIT Annual Combined General Meeting of May 24, 2023 — Availability of Preparatory Documents Exhibit 99.1 GENFIT Annual Combined General Meeting of May 24, 2023 — Availability of Preparatory Documents Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 19, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced that it published in th |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 19, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal exe |
|
| April 19, 2023 |
Exhibit 99.2 APRIL 19, 2023 FRENCH OFFICIAL LEGAL ANNOUNCEMENTS PUBLICATION «BALO» BULLETIN N°47 This document has been translated in English for information only. In the event of any differences between the French text and the English text, the French language version shall supersede. SHAREHOLDERS' AND UNITHOLDERS' MEETINGS GENFIT French public limited company (Société Anonyme) with a Board of Di |
|
| April 18, 2023 |
As filed with the Securities and Exchange Commission on April 18, 2023 As filed with the Securities and Exchange Commission on April 18, 2023 Registration No. |
|
| April 18, 2023 |
As filed with the Securities and Exchange Commission on April 18, 2023 As filed with the Securities and Exchange Commission on April 18, 2023 Registration No. |
|
| April 18, 2023 |
Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of GENFIT S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Pascal Prigent, C |
|
| April 18, 2023 |
Calculation of Filing Fee Tables Exhibit 107 CALCULATION OF FILING FEE TABLE Form F-3 (Form Type) GENFIT S.A. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forwar |
|
| April 18, 2023 |
Summary of 2023 Share Option Plan Exhibit 4.12 Summary of the 2023 Stock Options Plans Stock options (options de souscription et/ou d’achat d’actions) are granted for free and entitle each holder to subscribe for new shares and/or purchase existing shares of our Company at an exercise price set at the time of grant. Administration. Pursuant to delegations granted at our general meeting of the shareholders, our board of directors d |
|
| April 18, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) GENFIT S.A. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, €0.25 nominal value per shar |
|
| April 18, 2023 |
Summary of 2023 Free Shares (AGA) Plan Exhibit 4.6 Summary of 2023 Free Shares (AGA) Plans Free shares or AGA (actions gratuites) are shares of our Company that are granted to the beneficiary for free. They vest (i.e. the grant becomes definitive) after a minimum vesting period of one (1) year and can be subject to a lock-up period of at least one (1) further year. The sum of the vesting period and the lock-up period cannot be less tha |
|
| April 18, 2023 |
Amended and Restated Terms and Conditions of the OCEANE convertible bonds dated January 21, 2021 Exhibit 4.17 GENFIT French société anonyme with a board of directors with a share capital of € 7,791,609.25 Registered office: Parc Eurasanté, 885, avenue Eugène Avinée, 59120 Loos, France 424 341 907 R.C.S. Lille Métropole GENFIT 3.50 per cent. bonds issue for a nominal amount of € 179,999,997.60 due 16 October 2025 convertible into new Shares and/or exchangeable for existing Shares of GENFIT AME |
|
| April 18, 2023 |
Summary of 2022 Share Option Plans Exhibit 4.11 Summary of the 2022 Stock Options Plans Stock options (options de souscription et/ou d’achat d’actions) are granted for free and entitle each holder to subscribe for new shares and/or purchase existing shares of our Company at an exercise price set at the time of grant. Administration. Pursuant to delegations granted at our general meeting of the shareholders, our board of directors d |
|
| April 18, 2023 |
Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of GENFIT S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Thomas Baetz, Chi |
|
| April 18, 2023 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Pascal Prigent, certify that: 1.I have reviewed this annual report on Form 20-F of GENFIT S.A.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to |
|
| April 18, 2023 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Thomas Baetz, certify that: 1.I have reviewed this annual report on Form 20-F of GENFIT S.A.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to s |
|
| April 18, 2023 |
Exhibit 2.3 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the ordinary shares, the American Depositary Shares and the articles of association, or bylaws, of GENFIT S.A. (“Genfit” or the “Company”) is a summary and does not purport to be complete. This summary is subject to, and qualified in its entirety by reference |
|
| April 18, 2023 |
Summary of 2022 Free Shares (AGA) Plan Exhibit 4.5 Summary of 2022 Free Shares (AGA) Plans Free shares or AGA (actions gratuites) are shares of our Company that are granted to the beneficiary for free. They vest (i.e. the grant becomes definitive) after a minimum vesting period of one (1) year and can be subject to a lock-up period of at least one (1) further year. The sum of the vesting period and the lock-up period cannot be less tha |
|
| April 18, 2023 |
Exhibit 99.1 GENFIT Announces Publication of the 2022 Universal Registration Document and the 2022 Annual Report on Form 20-F Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 18, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced the f |
|
| April 18, 2023 |
Articles of Association of GENFIT S.A. (English translation) Exhibit 1.1 GENFIT SA Corporation with a Board of Directors and a share capital of € 12,458,745.75 Registered office: Parc Eurasanté, 885 Avenue Eugène Avinée, 59120 LOOS 424 341 907 R.C.S. LILLE Métropole ARTICLES OF ASSOCIATION Updated as of September 16, 2022 1 PART I FORM - NAME - REGISTERED OFFICE - PURPOSE - TERM ARTICLE 1 - Form The owners of the shares created below and of those that may b |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 18, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal exe |
|
| April 18, 2023 |
Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 14, 2023 |
Exhibit 99.1 GENFIT Reports Full-Year 2022 Financial Results and Provides Corporate Update • Cash, cash equivalents and current financial assets totaled €140.2 million1 as of December 31, 2022, expected to fund operations through third quarter 2024 • Transformative milestone expected towards end of second quarter 2023, with topline data readout for Phase 3 ELATIVE® evaluating elafibranor in primar |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 13, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal exe |
|
| February 28, 2023 |
GENFIT Announces Revenues and Cash Position as of December 31, 2022 Exhibit 99.1 GENFIT Announces Revenues and Cash Position as of December 31, 2022 – Cash, cash equivalents and current financial instruments totaled €140.2 million as of December 31, 2022. Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); February 28, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of p |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: February 28, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal |
|
| January 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 30, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal e |
|
| January 30, 2023 |
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial Exhibit 99.1 GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 30, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced the ha |
|
| January 24, 2023 |
GENFIT Announces 2023 Financial Calendar Exhibit 99.1 GENFIT Announces 2023 Financial Calendar Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 24, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced its provisional financial calendar for 2023. 2023 |
|
| January 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 24, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal e |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 5, 2023 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant?s name into English) Parc Eurasant? 885, avenue Eug?ne Avin?e 59120 Loos, France (Address of principal ex |
|
| January 5, 2023 |
GENFIT to Participate in Upcoming Investor Conferences EX-99.1 2 exh991.htm EXHIBIT 99.1 Exhibit 99.1 GENFIT to Participate in Upcoming Investor Conferences Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 5, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced th |
|
| November 17, 2022 |
GENFIT Pipeline Day Highlights Diverse Product Portfolio in Underserved Liver Diseases Exhibit 99.1 GENFIT Pipeline Day Highlights Diverse Product Portfolio in Underserved Liver Diseases ? Phase 3 data for elafibranor in primary biliary cholangitis (PBC) expected in 2Q23 ? Expanded pipeline now covers five therapeutic areas with high unmet medical need via six independent programs exploring the potential of differentiated mechanisms of action ? A regular stream of new clinical data |
|
| November 17, 2022 |
6-K 1 f6k111722.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 17, 2022 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant's name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 10, 2022 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant's name into English) Parc Eurasant? 885, avenue Eug?ne Avin?e 59120 Loos, France (Address of principal |
|
| November 10, 2022 |
GENFIT Reports Third Quarter 2022 Financial Information Exhibit 99.1 GENFIT Reports Third Quarter 2022 Financial Information ? Cash and cash equivalents: ?163.6 million as of September 30, 2022 Lille, France; Cambridge, MA; November 10, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced its cash position as of September 30, 20 |
|
| October 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: October 25, 2022 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant's name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France (Address of principal e |
|
| October 25, 2022 |
Exhibit 99.1 GENFIT Announces Compelling Results for Next-Generation Non- Invasive Diagnostic Technology NIS2+™ in NASH to be Presented at the AASLD Liver Meeting® § NIS2+™ developed and validated as an optimization of NIS4® technology for the detection of patients with at-risk NASH § Data demonstrate robust and improved clinical performance of NIS2+™ allowing an efficient identification of at-ris |
|
| September 29, 2022 |
Exhibit 99.1 GENFIT Announces Signature of the Share Purchase Agreement and the Completion of its Acquisition of Versantis Lille (France), Cambridge (Massachusetts, United States), September 29, 2022 ? GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced the signing of the Share P |
|
| September 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 29, 2022 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant's name into English) Parc Eurasant? 885, avenue Eug?ne Avin?e 59120 Loos, France (Address of principal |
|
| September 28, 2022 |
GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update PRESS RELEASE GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update ?Financial highlights ?Cash and cash equivalents totaled ?209 million as of June 30, 2022 ?Net loss totaled ?10 million for the first half 2022 ?Developments in our programs ?Patient enrollment for the double-blind part of the Phase 3 study in Primary Biliary Cholangitis (PBC) ELATIVETM completed at t |
|
| September 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 28, 2022 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant?s name into English) Parc Eurasant? 885, avenue Eug?ne Avin?e 59120 Loos, France (Address of principal |
|
| September 28, 2022 |
Half-Year Business and Financial Report at June 30, 2022 GENFIT | 2021 Table of Contents 1. |
|
| September 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 19, 2022 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant?s name into English) Parc Eurasant? 885, avenue Eug?ne Avin?e 59120 Loos, France (Address of principal |
|
| September 19, 2022 |
Exhibit 99.1 GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver Diseases ? Further consolidates GENFIT?s position as a leader in acute-on-chronic liver failure (ACLF) ? Significantly expands GENFIT?s pipeline with VS-01-ACLF, a Phase 2 ready program based on first-in-class scavenging liposomes technology, VS-01-UCD, a pediatric program focused on |
|
| September 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 13, 2022 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant?s name into English) Parc Eurasant? 885, avenue Eug?ne Avin?e 59120 Loos, France (Address of principal |
|
| September 13, 2022 |
FDA Grants GENFIT’s GNS561 Orphan Drug Designation for the Treatment of Cholangiocarcinoma Exhibit 99.1 FDA Grants GENFIT?s GNS561 Orphan Drug Designation for the Treatment of Cholangiocarcinoma Lille (France), Cambridge (Massachusetts, United States), September 13, 2022 ? GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced that the U.S. Food and Drug Administration (F |
|
| July 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 08, 2022 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant?s name into English) Parc Eurasant? 885, avenue Eug?ne Avin?e 59120 Loos, France (Address of principal exec |
|
| July 8, 2022 |
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial EX-99.1 2 exh991.htm EXHIBIT 99.1 Exhibit 99.1 GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial Lille, France; Cambridge, MA; July 08, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced the half-year report of the liquidity contract with |
|
| May 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 25, 2022 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant?s name into English) Parc Eurasant? 885, avenue Eug?ne Avin?e 59120 Loos, France (Address of principal execu |
|
| May 25, 2022 |
GENFIT: May 25, 2022 Combined Shareholders Meeting results Exhibit 99.1 GENFIT: May 25, 2022 Combined Shareholders Meeting results ? Quorum of 25.16% on first convening; allowing approval of all the resolutions submitted by the Board of Directors Lille, France; Cambridge, MA; May 25, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today annou |
|
| May 11, 2022 |
GENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS) Exhibit 99.1 GENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS) - Cash and cash equivalents totaled ?222.2 million as of March 31, 2022 Lille, France; Cambridge, MA; May 11, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announc |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 11, 2022 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant?s name into English) Parc Eurasant? 885, avenue Eug?ne Avin?e 59120 Loos, France (Address of principal execu |
|
| April 29, 2022 |
Exhibit 2.4 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the ordinary shares, the American Depositary Shares and the articles of association, or bylaws, of GENFIT S.A. (?Genfit? or the ?Company?) is a summary and does not purport to be complete. This summary is subject to, and qualified in its entirety by reference |
|
| April 29, 2022 |
Summary of 2021 Free Shares (AGA) Plan Exhibit 4.5 Summary of 2021 Free Shares (AGA) Plans Free shares or AGA (actions gratuites) are shares of our Company that are granted to the beneficiary for free. They vest (i.e. the grant becomes definitive) after a minimum vesting period of one (1) year and can be subject to a lock-up period of at least one (1) further year. The sum of the vesting period and the lock-up period cannot be less tha |
|
| April 29, 2022 |
Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of GENFIT S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Pascal Prigent, C |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 29, 2022 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Thomas Baetz, certify that: 1.I have reviewed this annual report on Form 20-F of GENFIT S.A.; 1.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to s |
|
| April 29, 2022 |
Collaboration and License Agreement between the registrant and [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) CUSTOMARILY AND ACTUALLY TREATED BY THE REGISTRANT AS PRIVATE OR CONFIDENTIAL. |
|
| April 29, 2022 |
Exhibit 99.1 GENFIT Announces Publication of the 2021 Universal Registration Document; the 2021 Annual Report on Form 20-F and Availability of Preparatory Documents for the Annual Combined Shareholders Meeting on May 25, 2022 Lille, France; Cambridge, MA; April 29, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late- stage biopharmaceutical company dedicated to improving the lives of patients with s |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: Friday April 29, 2022 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant?s name into English) Parc Eurasant? 885, avenue Eug?ne Avin?e 59120 Loos, France (Address of princi |
|
| April 29, 2022 |
Summary of 2021 Share Option Plans Exhibit 4.9 Summary of the 2021 Stock Options Plans Stock options (options de souscription et/ou d?achat d?actions) are granted for free and entitle each holder to subscribe for new shares and/or purchase existing shares of our Company at an exercise price set at the time of grant. Administration. Pursuant to delegations granted at our general meeting of the shareholders, our board of directors de |
|
| April 29, 2022 |
Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of GENFIT S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Thomas Baetz, Chi |
|
| April 29, 2022 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Pascal Prigent, certify that: 1.I have reviewed this annual report on Form 20-F of GENFIT S.A.; 1.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to |
|
| April 29, 2022 |
Articles of Association of GENFIT S.A. (English translation) Exhibit 1.2 GENFIT SA Corporation with a Board of Directors and a share capital of € 12,453,872.25 Registered office: Parc Eurasanté, 885 Avenue Eugène Avinée, 59120 LOOS 424 341 907 R.C.S. LILLE Métropole ARTICLES OF ASSOCIATION Updated as of December 22, 2021 1 PART I FORM - NAME - REGISTERED OFFICE - PURPOSE - TERM ARTICLE 1 - Form The owners of the shares created below and of those that may be |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 27, 2022 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant?s name into English) Parc Eurasant? 885, avenue Eug?ne Avin?e 59120 Loos, France (Address of principal exe |
|
| April 27, 2022 |
Exhibit 99.1 APRIL 20, 2022 FRENCH OFFICIAL LEGAL ANNOUNCEMENT PUBLICATION ?BALO? BULLETIN N?47 This document has been translated in English for information only. In the event of any differences between the French text and the English text, the French language version shall supersede. SHAREHOLDERS' AND UNITHOLDERS' MEETINGS GENFIT French public limited company (Soci?t? Anonyme) with a Board of Dir |
|
| April 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 20, 2022 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant?s name into English) Parc Eurasant? 885, avenue Eug?ne Avin?e 59120 Loos, France (Address of principal exe |
|
| April 20, 2022 |
GENFIT Annual Combined General Meeting of May 25, 2022 - Availability of Preparatory Documents Exhibit 99.1 GENFIT Annual Combined General Meeting of May 25, 2022 - Availability of Preparatory Documents Lille, France; Cambridge, MA; April 20, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late- stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced that it published in the April 20, 2022 French legal announcements bulle |
|
| April 7, 2022 |
GENFIT Reports Full-Year 2021 Financial Results and Provides Corporate Update Exhibit 99.1 GENFIT Reports Full-Year 2021 Financial Results and Provides Corporate Update ? Cash and cash equivalents totaled ?258.8 million as of December 31, 2021 ? Major financial achievements in 2021 include landmark strategic partnership deal with Ipsen, successful convertible debt renegotiation and non-dilutive funding through French State-Guaranteed Loans ? Important R&D milestones reached |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: Thursday April 7, 2022 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant?s name into English) Parc Eurasant? 885, avenue Eug?ne Avin?e 59120 Loos, France (Address of princ |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: February 28, 2022 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant?s name into English) Parc Eurasant? 885, avenue Eug?ne Avin?e 59120 Loos, France (Address of principal |
|
| March 1, 2022 |
GENFIT Announces Solid Revenues and Cash Position as of December 31, 2021 Exhibit 99.1 GENFIT Announces Solid Revenues and Cash Position as of December 31, 2021 ? Cash and cash equivalents totaled ?258.8 million as of December 31, 2021, which includes the ?120 million upfront payment and a ?28 million equity investment pursuant to the licensing agreement signed in December 2021 with Ipsen Lille, France; Cambridge, MA; February 28, 2022 - GENFIT (Nasdaq and Euronext: GNF |
|
| February 14, 2022 |
GNFTF / Genfit / CITADEL ADVISORS LLC - GENFIT S.A. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 1)* Genfit S.A. (Name of Issuer) Ordinary shares, ?0.25 par value per share (the ?Shares?) (Title of Class of Securities) 372279109 ** (CUSIP N |
|
| January 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 24, 2022 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant?s name into English) Parc Eurasant? 885, avenue Eug?ne Avin?e 59120 Loos, France (Address of principal e |
|
| January 24, 2022 |
GENFIT: 2022 Financial Calendar Exhibit 99.1 GENFIT: 2022 Financial Calendar Lille, France; Cambridge, MA; January 24, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced its provisional financial calendar for 2022. February 28, 2022: Publication of revenue and cash position at December 31, 2021 April 07 |
|
| December 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: December 17, 2021 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant?s name into English) Parc Eurasant? 885, avenue Eug?ne Avin?e 59120 Loos, France (Address of principal |
|
| December 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: December 17, 2021 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant?s name into English) Parc Eurasant? 885, avenue Eug?ne Avin?e 59120 Loos, France (Address of principal |
|
| December 17, 2021 |
On heels of global strategic partnership announced today, GENFIT acquires rights to novel asset Exhibit 99.1 On heels of global strategic partnership announced today, GENFIT acquires rights to novel asset ? Exclusive rights for a novel early-stage asset acquired from Genoscience Pharma in cholangiocarcinoma in the United States, Canada and Europe ? Phase 2 clinical program expected to start in 1H 2022 ? Agreement comes on the heels of today?s other announcement of a long-term global strategi |
|
| December 17, 2021 |
Paris (France); December 17, 2021 Exhibit 99.1 GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership - Agreement gives Ipsen global* rights to develop and commercialize GENFIT?s late- stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) - Investigational t |
|
| November 18, 2021 |
Exhibit 99.1 GENFIT: FNIH NIMBLE Study Demonstrates NIS4? Technology?s Unique Performance in Identifying Patients with ?at-risk? NASH Lille, France; Cambridge, MA; November 18, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, is proud to announce that NIS4? technology?s utility |
|
| November 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: 18 November, 2021 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant?s name into English) Parc Eurasant? 885, avenue Eug?ne Avin?e 59120 Loos, France (Address of principal |
|
| November 9, 2021 |
Exhibit 99.1 GENFIT Announces First Patient First Visit for the Evaluation of NTZ in Subjects with Hepatic Impairment as part of its ACLF Program Lille, France; Cambridge, MA; November 09, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced the first patient first v |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 09, 2021 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant?s name into English) Parc Eurasant? 885, avenue Eug?ne Avin?e 59120 Loos, France (Address of principal |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 08, 2021 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant?s name into English) Parc Eurasant? 885, avenue Eug?ne Avin?e 59120 Loos, France (Address of principal |
|
| November 8, 2021 |
GENFIT: Third Quarter 2021 Financial Information Exhibit 99.1 GENFIT: Third Quarter 2021 Financial Information - Cash and cash equivalents: ?91.5 million as of September 30, 2021 Lille, France; Cambridge, MA; November 8, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced its cash position as of September 30, 2021 |
|
| November 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 02, 2021 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant's name into English) Parc Eurasant? 885, avenue Eug?ne Avin?e 59120 Loos, France (Address of principal |
|
| November 2, 2021 |
Exhibit 99.1 New Clinical Data on GENFIT?s Investigational Compound Elafibranor to be Presented at AASLD The Liver Meeting? Lille, France; Cambridge, MA; November 02, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced that it will be presenting new clinical data on |
|
| September 29, 2021 |
GENFIT Reports First Half-Year 2021 Financial Results and Provides Corporate Update Exhibit 99.1 GENFIT Reports First Half-Year 2021 Financial Results and Provides Corporate Update - Financial highlights o Cash and cash equivalents totaled ?104 million as of June 30, 2021 (including ?11 million non-dilutive financing obtained in the first half 2021) o Net income totaled ?9 million for the first half 2021, due to a one-off revenue following the successful outcome of the convertibl |
|
| September 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 29, 2021 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant?s name into English) Parc Eurasant? 885, avenue Eug?ne Avin?e 59120 Loos, France (Address of principal |
|
| July 9, 2021 |
6-K 1 f6k070921.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 09, 2021 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant’s name into English) Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, Fran |
|
| July 9, 2021 |
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial Exhibit 99.1 GENFIT: Half-Year Report of Liquidity Contract with Cr?dit Industriel et Commercial Lille, France; Cambridge, MA; July 09, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the half-year report of the liquidity contract with Cr?dit Industriel et Commercial. U |
|
| June 30, 2021 |
GENFIT: June 30, 2021 Annual Shareholders Meeting results Exhibit 99.1 GENFIT: June 30, 2021 Annual Shareholders Meeting results Lille (France); Cambridge (Massachusetts, United States) ? June 30, 2021 ? GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced the results of the voting by shareholders at the Combined Shareholders Meet |
|
| June 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 30, 2021 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant?s name into English) Parc Eurasant? 885, avenue Eug?ne Avin?e 59120 Loos, France (Address of principal exec |
|
| June 24, 2021 |
GENFIT obtains non-dilutive financing of €11 million in the form of a State Guaranteed Loan Exhibit 99.1 GENFIT obtains non-dilutive financing of ?11 million in the form of a State Guaranteed Loan Lille, France; Cambridge, MA; June 24, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late- stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the securing of a ?11 million non-dilutive loan guaranteed by the French gove |
|
| June 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 24, 2021 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant?s name into English) Parc Eurasant? 885, avenue Eug?ne Avin?e 59120 Loos, France (Address of principal exec |
|
| June 21, 2021 |
18 JUNE 2021 FRENCH OFFICIAL LEGAL ANNOUNCEMENT PUBLICATION ?BALO? BULLETIN N?73 This document has been translated in English for information only. |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 18, 2021 Commission File Number: 001-38844 GENFIT S.A. (Translation of registrant?s name into English) Parc Eurasant? 885, avenue Eug?ne Avin?e 59120 Loos, France (Address of principal exec |
